Malignant Mesothelioma (eBook, PDF)

Pathogenesis, Diagnosis, and Translational Therapies
Redaktion: Pass, Harvey I.; Carbone, Michele; Vogelzang, Nicholas

• Format: PDF

Produktbeschreibung

Malignant Mesothelioma brings together the most current diagnostic criteria and treatment plans from the world's leading experts on this rare but devastating cancer. The first edition was a critical and commercial success and this revision builds on that reputation. The editors have brought together the world's leading experts to fully explore the latest scientific breakthroughs in carcinogenesis, immunotherapy, potential vaccination strategies, and gene therapy. The clinical aspects of the book are equally strong, with thorough discussion of epidemiology, etiology, different clinical presentations, imaging (including interventional pulmonology), treatment of benign disease, strategies for multimodality treatment of malignant disease.

Editors: Harvey I. Pass, M.D, Chief, Thoracic Surgery, New York University, New York, NY; Nicholas Vogelzang, M.D, Director, Nevada Cancer Institute, Las Vegas, NV; University of Chicago, Michele Carbone, M.D., Ph.D, Researcher and Director, Thoracic Oncology Program, Cancer Research Center of Hawaii, Honolulu, HI; and Anne S. Tsao, M.D, Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Springer New York
• Seitenzahl: 854
• Erscheinungstermin: 1. August 2006
• Englisch
• ISBN-13: 9780387282749
• Artikelnr.: 37286926

Autorenporträt

Harvey I. Pass, Wayne State University, Detroit, MI, USA / Nicholas Vogelzang, University of Chicago, IL, USA / Michele Carbone, Loyola University, Maywood, IL, USA

Inhaltsangabe

Carcinogenesis.- The History of Mesothelioma.- Asbestos-Induced Mesothelioma.- SV40-Mediated Oncogenesis.- Mesothelioma Carcinogenesis: In Vivo Models.- Mesothelial and Mesothelioma Cell Lines.- Molecular Genetics.- Cytogenetics of Malignant Mesothelioma.- Growth Factors and Malignant Mesothelioma.- Oncogenes and Tumor Suppressor Genes in Malignant Mesothelioma.- Angiogenesis and Mesothelioma.- Immune Status and Mesothelioma.- Extracellular Matrix and Mesothelioma: Some Clues to the Invasive Behavior of Mesothelioma.- Genomics and Proteomics in Mesothelioma.- Epidemiology.- Asbestos Mineralogy and Health Effects.- Molecular Epidemiology of Mesothelioma.- Malignant Mesothelioma and Erionite.- Determination of Asbestos Exposure by Pathology and Clinical History.- Mesothelioma and Asbestos Exposure.- From Monkey to Man: The Epidemiologic Evidence of an Association Between Simian Virus 40 and Malignancy.- Causes and Prevention of Technical Artifacts When Studying Simian Virus 40 (SV40) in Human Mesotheliomas.- Molecular Detection of Siman Virus 40 in Human Mesothelioma.- Malignant Mesothelioma Following Radiation.- Genetics and Human Mesothelioma.- Clinical Presentation.- Clinicians' Approach to Mesothelioma.- Clinical Presentation and Natural History of Mesothelioma: Pleural and Pericardial.- Clinical Presentation and Natural History of Mesothelioma: Abdominal.- Staging of Mesothelioma.- Prognostic Factors in Mesothelioma.- Imaging and Endoscopy.- Radiologic Assessment of Mesothelioma.- Endoscopic Imaging.- Pathology.- Benign Mesotheliomas, Mesothelial Proliferations, and Their Possible Association with Asbestos Exposure.- Cytology of Malignant Mesothelioma.- Immunohistochemistry.- Malignant Mesothelioma Electron Microscopy.- Rare Variants of Mesothelioma.-Differentiating Sarcomas from Mesotheliomas.- Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma.- Pitfalls in the Diagnosis of Malignant Mesothelioma.- Treatment.- Management of Benign Variants of Mesothelioma.- First-Line Chemotherapy for Malignant Pleural Mesothelioma.- Second-Line Chemotherapy.- Treatment of Mesothelioma with Radiotherapy.- Multimodality Approaches.- Intrapleural Chemotherapy with and Without Surgery in Malignant Pleural Mesothelioma (MPM).- Management of Pleural Effusions in Mesothelioma.- Preoperative Chemotherapy and Surgery.- Photodynamic Therapy for Pleural Mesothelioma.- Surgery and Postoperative Radiotherapy.- The Development of the Brigham and Women's Multimodality Treatment Plan for Malignant Pleural Mesothelioma: A Model for Improving the Treatment of Rare Diseases.- Peritoneal Mesothelioma: The Columbia Experience.- Surgery, Hyperthermic Chemoperfusion, and Postoperative Chemotherapy: The National Cancer Institute and Washington Hospital Center Experience.- Pericardial and Tunica Vaginalis Mesothelioma.- Novel Treatment Strategies.- New Target Therapies for Malignant Mesothelioma.- Gene Therapy for Malignant Pleural Mesothelioma.- Immunotherapeutic Approaches and Vaccination Strategies.- Economic Implications.- Economic Aspects of Mesothelioma.

Rezensionen

From the reviews: "Malignant Mesothelioma is an uncommon neoplasm usually associated with exposure to asbestos. ... Harvey Pass and colleagues have edited an up-to-date, comprehensive book that includes a wide range of information, from a historical perspective to descriptions of the latest treatment. ... Laboratory researchers will use it as a resource for information ... of mesothelioma. ... Clinicians will benefit from this complete guide ... . I highly recommend this book to all those who are interested in mesothelioma." (Julie R. Brahmer, The New England Journal of Medicine, March, 2006) "This is a reference book suitable for departmental and medical libraries and for the shelves of those who have a particular clinical or research interest in mesothelioma ... . Pass, Vogelzang and Carbone envisioned a comprehensive text and have achieved it. ... To be useful such a book must be well indexed; and this is. The individual chapters are well referenced ... . The text is well edited ... . This is a quality production. ... Overall it is highly recommended." (Michael Byrne, CancerForum, Vol. 30 (3), November, 2006)